Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 2/20 | 0.47 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.42 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.42 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.41 |
| ▸ | GPR119 | Q8TDV5 | 9/20 | 0.39 |
| ▸ | FAAH | O00519 | 1/20 | 0.37 |
| ▸ | MMP1 | P03956 | 1/20 | 0.35 |
| ▸ | MMP3 | P08254 | 1/20 | 0.35 |
| ▸ | MMP7 | P09237 | 1/20 | 0.35 |
| ▸ | MMP9 | P14780 | 1/20 | 0.35 |
| ▸ | MMP8 | P22894 | 1/20 | 0.35 |
| ▸ | MMP13 | P45452 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12282871 | 1.00 | DPP4 (0.47) | DPP4PDE4BHSD11B1DPP7GPR119 | |
| SCHEMBL287966 | 0.89 | GPR119 (0.44) | DPP4PDE4BGPR119FAAHMMP1 | |
| SCHEMBL12206738 | 0.84 | CHRNB2 (0.38) | DPP4PDE4BHSD11B1GPR119 | |
| SCHEMBL13752388 | 0.83 | DPP4 (0.54) | DPP4HSD11B1DPP7GPR119 | |
| SCHEMBL23733975 | 0.83 | DPP4 (0.43) | DPP4PDE4BHSD11B1DPP7 | |
| SCHEMBL12283101 | 0.81 | ALDH1A1 (0.46) | DPP4PDE4BHSD11B1DPP7GPR119 | |
| SCHEMBL12282677 | 0.81 | ALDH1A1 (0.46) | DPP4PDE4BHSD11B1DPP7GPR119 | |
| SCHEMBL13186495 | 0.81 | ALDH1A1 (0.46) | DPP4PDE4BHSD11B1DPP7GPR119 | |
| SCHEMBL1942044 | 0.79 | CHRNB2 (0.46) | DPP4PDE4BDPP7 | |
| SCHEMBL6484170 | 0.79 | CHRNB2 (0.46) | DPP4PDE4BDPP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102395584-A | Compounds for the treatment of metabolic disorders | PROSIDION LTD | 2012-03-28 | — | — | CN | disclosed |
| US-20120040953-A1 | Compounds for the Treatment of Metabolic Disorders | PROSIDION LIMITED (GB) | 2012-02-16 | — | — | US | disclosed |
| US-20120040953-A1 | Compounds for the Treatment of Metabolic Disorders | PROSIDION LIMITED (GB) | 2012-02-16 | — | — | US | disclosed |
| US-20120040953-A1 | Compounds for the Treatment of Metabolic Disorders | PROSIDION LIMITED (GB) | 2012-02-16 | — | — | US | disclosed |
| EP-2406256-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | Prosidion Limited (GB) | 2012-01-18 | — | — | EP | disclosed |
| WO-2010103335-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | PROSIDION LIMITED (GB) | 2010-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120040953-A1 | Compounds for the Treatment of Metabolic Disorders | GPR119, GPR132, FFAR2 | DPP4 217/4885PDE4B 451/4885HSD11B1 560/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.